Eli Lilly is seeking approval to add its diabetes drug, Tirzepatide, to the US weight loss market after a successful clinical trial. Tirzepatide, taken once a week as an injection, led to an average weight loss of 15.7% in overweight or obese participants with type 2 diabetes. The drug mimics the gastrointestinal hormone GLP-1 and activates receptors in the brain involved in appetite regulation. The obesity treatments market could be worth $54bn by 2030, and Eli Lilly expects regulatory action on its submission as early as late 2023. Novo Nordisk has already marketed its weight loss drug, Wegovy, using a similar chemical.
Source:https://www.sciencealert.com/new-weight-loss-drug-may-launch-in-us-after-promising-clinical-trial
